Japan’s recent Upper House election delivered a stinging defeat for the ruling Liberal Democratic Party (LDP) and junior coalition partner…
REGULATORY
Chuikyo OKs Taltz, Micatrio for Listing on Nov. 18; Keytruda Takes Pass This Time
The health ministry’s Central Social Insurance Medical Council (Chuikyo) on November 9 approved 23 brands for NHI price listing on November 18, including Eli Lilly’s psoriasis drug Taltz (ixekizumab), which skipped listing in August. MSD’s immuno-oncology drug Keytruda (pembrolizumab) was…
To read the full story
Related Article
- Taltz Finally Makes it to Japan Market after Pricing Flap
November 22, 2016
- Empliciti, Batch of Other Drugs Go on Sale in Japan
November 21, 2016
- Chuikyo Members Chide Unexplained Withdrawal of Taltz’s Listing Request
November 10, 2016
- MHLW Won’t Require Use of Other Psoriasis Drugs before Taltz
November 10, 2016
- MSD to Seek Keytruda Listing after Adding Lung Cancer Indication
November 10, 2016
REGULATORY
- Industry Urges “Objective Review First” for CEA Reform; Payers Push for Expansion
August 7, 2025
- Welireg, Airwin, Talvey and More Set for NHI Listing; Premiums Wiped Out by “Zero” Rule
August 7, 2025
- DPO Floats Premium Expansion, Relaxed Criteria towards FY2026 Reform
August 7, 2025
- Chuikyo Rules Out Long-Term Care Costs in Leqembi CEA, Confirms Price Cut
August 7, 2025
- Wegovy, Leqvio, Phozevel to Face CEA-Linked Price Cuts in November
August 7, 2025
A recent conversation with a US biopharma senior director highlighted a critical talent gap: a strong demand for individuals with strategic management, critical thinking, and advanced business acumen-skills beyond traditional operational excellence. After the conversation, I rushed home and picked…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s key reimbursement policy panel on December 25 approved an outline of the FY2025 drug price revision, finalizing plans to…
For the first time in many years, Japan appeared to have pivoted to a pro-innovation path with the FY2024 drug pricing reform. All eyes were apparently on this course change as seen in this year’s most-read story list, though the…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
The Ministry of Health, Labor and Welfare (MHLW) posted the final report compiled by its pharmaceutical regulation panel on its website on April 24, providing cases of drugs that could be exempted from all-case post marketing surveillance (PMS).The MHLW plans…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…